109 related articles for article (PubMed ID: 33866341)
1. The application of
Dębiec K; Wydmański J; d'Amico A; Gorczewska I; Krzywon A; Cortez AJ; Pelak MJ
Hell J Nucl Med; 2021; 24(1):66-74. PubMed ID: 33866341
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG PET/CT role in staging of gastric carcinomas: comparison with conventional contrast enhancement computed tomography.
Altini C; Niccoli Asabella A; Di Palo A; Fanelli M; Ferrari C; Moschetta M; Rubini G
Medicine (Baltimore); 2015 May; 94(20):e864. PubMed ID: 25997066
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic accuracy of
Lemans JVC; Hobbelink MGG; IJpma FFA; Plate JDJ; van den Kieboom J; Bosch P; Leenen LPH; Kruyt MC; Glaudemans AWJM; Govaert GAM
Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):999-1008. PubMed ID: 30523391
[TBL] [Abstract][Full Text] [Related]
5. Comparison of FDG PET/CT and MRI in lymph node staging of endometrial cancer.
Kim HJ; Cho A; Yun M; Kim YT; Kang WJ
Ann Nucl Med; 2016 Feb; 30(2):104-13. PubMed ID: 26546334
[TBL] [Abstract][Full Text] [Related]
6. Routinely staging gastric cancer with
Findlay JM; Antonowicz S; Segaran A; El Kafsi J; Zhang A; Bradley KM; Gillies RS; Maynard ND; Middleton MR
Eur Radiol; 2019 May; 29(5):2490-2498. PubMed ID: 30643947
[TBL] [Abstract][Full Text] [Related]
7. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT.
Yun M; Lim JS; Noh SH; Hyung WJ; Cheong JH; Bong JK; Cho A; Lee JD
J Nucl Med; 2005 Oct; 46(10):1582-8. PubMed ID: 16204706
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic performance of
Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
[TBL] [Abstract][Full Text] [Related]
10. Whole-body
Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
[TBL] [Abstract][Full Text] [Related]
11. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging
Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N
Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959
[TBL] [Abstract][Full Text] [Related]
12. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
Zhang X; Wu F; Han P
Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
14. Comparison of
Pang Y; Zhao L; Luo Z; Hao B; Wu H; Lin Q; Sun L; Chen H
Radiology; 2021 Feb; 298(2):393-402. PubMed ID: 33258746
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of 18-F Fluorodeoxyglucose Positron Emission Tomographic/Computed Tomographic Imaging in Primary Staging of Squamous Cell Carcinoma of the Oral Cavity.
Linz C; Brands RC; Herterich T; Hartmann S; Müller-Richter U; Kübler AC; Haug L; Kertels O; Bley TA; Dierks A; Buck AK; Lapa C; Brumberg J
JAMA Netw Open; 2021 Apr; 4(4):e217083. PubMed ID: 33881529
[TBL] [Abstract][Full Text] [Related]
16. Added value of pretreatment (18)F-FDG PET/CT for staging of advanced gastric cancer: Comparison with contrast-enhanced MDCT.
Kawanaka Y; Kitajima K; Fukushima K; Mouri M; Doi H; Oshima T; Niwa H; Kaibe N; Sasako M; Tomita T; Miwa H; Hirota S
Eur J Radiol; 2016 May; 85(5):989-95. PubMed ID: 27130061
[TBL] [Abstract][Full Text] [Related]
17. Should 18F-FDG PET/CT Be Routinely Performed in the Clinical Staging of Locally Advanced Gastric Adenocarcinoma?
Perlaza P; Ortín J; Pagès M; Buxó E; Fernández-Esparrach G; Colletti PM; Rubello D; Mayoral M; Sánchez N; Ruiz C; Ginés A; Fuster D
Clin Nucl Med; 2018 Jun; 43(6):402-410. PubMed ID: 29485442
[TBL] [Abstract][Full Text] [Related]
18. Implications of false negative and false positive diagnosis in lymph node staging of NSCLC by means of ¹⁸F-FDG PET/CT.
Li S; Zheng Q; Ma Y; Wang Y; Feng Y; Zhao B; Yang Y
PLoS One; 2013; 8(10):e78552. PubMed ID: 24205256
[TBL] [Abstract][Full Text] [Related]
19. Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients.
Fleming AJ; Smith SP; Paul CM; Hall NC; Daly BT; Agrawal A; Schuller DE
Laryngoscope; 2007 Jul; 117(7):1173-9. PubMed ID: 17603315
[TBL] [Abstract][Full Text] [Related]
20. Staging FDG PET-CT changes management in patients with gastric adenocarcinoma who are eligible for radical treatment.
Bosch KD; Chicklore S; Cook GJ; Davies AR; Kelly M; Gossage JA; Baker CR
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):759-767. PubMed ID: 31377821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
